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Schizophrenia and bipolar disorders share some genetic
risk factors and are similar in several epidemiologic fea-
tures. Some data in family and twin studies suggest hered-
itary overlap between the two disorders. Despite the
availability of official diagnostic criteria, the diagnosis of
bipolar disorder is still problematic. Both nosologic enti-
ties describe psychotic disorders, have similar ages at
onset and are lifelong conditions. A bipolar continuum
theory supports the concept of a psychiatric continuum
from unipolar to bipolar disorder and scizophrenia. The
diagnosis of schizoaffective disorder, which falls between
schizophrenia and bipolar disorders provides support for
the continuum theory of these illnesses. However, there
are clear clinical distinctions between these two nosologi-
cal categories according to ICD-10 and DSM-IV and lith-
ium therapy is effective in the majority of bipolar patients,
whereas few patients with schizophrenia are helped.
Regardless of whether bipolar disorders and schizophre-
nia are heterogenous, the most important clinical need is
to find safe and effective treatments for these disorders.
The similar abnormalities in neurotransmitter systems
between bipolar disorders and schizophrenia may
account for the efficacy of some newer atypical antipsy-
chotics, such as olanzapine and risperidone in the treat-
ment of patients with bipolar disorder. The antimanic
effect of olanzapine and risperidone is attributed to block-
ade of dopamine D2 receptors and antagonism of
serotonin5-HT2A receptors. Although these atypical
antipsychotics were studied and marketed for the treat-
ment of schizoprenia are now approved for the treatment
of bipolar disorder. The biological similarities between
the two disorders will help us in the understanding of
bipolar disorder and the development of more effective
treatment strategies. In clinical practice, the diagnostic
separation of bipolar disorder from schizophrenia may be
difficult, but it is important because of the availability of
specific and effective treatments for each entity. Misdiag-
nosis can result in inappropriate prolonged use of antip-
sychotics, ineffective treatment with mood stabilizers,
treatment failure and unwanted effects, while antidepres-
sants may be associated with rapid cycling and a switch
from depression to mania.
from International Society on Brain and Behaviour: 1st International Congress on Brain and Behaviour
Hyatt Regency Hotel, Thessaloniki, Greece, 20–23 November, 2003
Published: 23 December 2003
Annals of General Hospital Psychiatry 2003, 2(Suppl 1):S43
Received: 1 November 2003
<supplement> <title> <p>International Society on Brain and Behaviour: 1st International Congress on Brain and Behaviour</p> </title> <note>Meeting abstracts</note> </supplement>
This article is available from: http://www.general-hospital-psychiatry.com/content/2/S1/S43
